Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Abstract: The present application provides a mounting base, a battery and a power consuming device, which relate to the technical field of batteries. The mounting base may be configured to be connected to an end plate and an output electrode, and an insulating structure may be provided on one side of the end plate and configured to insulate the end plate from a battery cell. The mounting base may include a main body provided with a flow guiding groove on the side facing the insulating structure. The flow guiding groove may be configured to prevent an electrical connection between the output electrode and the end plate by means of a liquid between the main body and the insulating structure.

Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: The present application discloses a negative electrode, a secondary battery and a device comprising the same. The negative electrode includes: a current collector; a first active material layer close to the current collector, the first active material layer including a first active material; and a second active material layer disposed on a surface of the first active material layer away from the current collector, the second active material layer including a second active material; wherein the first active material and the second active material are independently oval-like particles with through holes and/or blind holes, and the first active material has an average pore size greater than that of the second active material.

Abstract: The present invention provides compounds of Formula I?, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: The present application provides a mounting base, a battery and a power consuming device, which relate to the technical field of batteries. The mounting base may be configured to be connected to an end plate and an output electrode, and an insulating structure may be provided on one side of the end plate and configured to insulate the end plate from a battery cell. The mounting base may include a main body provided with a flow guiding groove on the side facing the insulating structure. The flow guiding groove may be configured to prevent an electrical connection between the output electrode and the end plate by means of a liquid between the main body and the insulating structure.

Abstract: The present application discloses a negative electrode, a secondary battery and a device comprising the same. The negative electrode includes: a current collector; a first active material layer close to the current collector, the first active material layer including a first active material; and a second active material layer disposed on a surface of the first active material layer away from the current collector, the second active material layer including a second active material; wherein the first active material and the second active material are independently oval-like particles with through holes and/or blind holes, and the first active material has an average pore size greater than that of the second active material.

Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Abstract: The disclosure provides compounds of Formula I, deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

Abstract: The disclosure provides at least one compound, reiterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), reiterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Abstract: The disclosure provides at least one entity chosen from compounds of Formula (I) pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.